UBS Group
AVDL

UBS Group’s Avadel Pharmaceuticals AVDL Stock Holding History

UBS Group’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-24,400
Closed -$239K – 10241
2021
Q3 		$239K Buy
+24,400
New +$192K ﹤0.01% 5188

Other funds holding AVDL

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS Group's AVDL Position: Q1 2026 in Review

UBS Group sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 344,933 shares — an estimated $7.43M sold.

UBS Group first reported a position in AVDL in Q4 2014 and held it in 45 quarters. The position peaked at $16.5M in Q4 2024. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

  • UBS Group reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • UBS Group sold 344,933 Avadel Pharmaceuticals shares in Q1 2026, an estimated $7.43M.
  • UBS Group first reported a position in Avadel Pharmaceuticals in Q4 2014 and held it in 45 quarters.
  • UBS Group's Avadel Pharmaceuticals position peaked at $16.5M in Q4 2024.
  • 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.